Key takeaways
- Subcutaneous (SubQ) injection of testosterone produces equivalent absorption to intramuscular (IM) with smoother peaks, less injection-site discomfort, smaller needles, and easier self-administration.
- The Spratt et al. and Kaminetsky et al. studies showed SubQ produces stable serum testosterone with reduced peak-trough variation versus traditional IM.
- Intramuscular places the oil into muscle — most often the gluteal muscle, the vastus lateralis in the outer thigh, or the deltoid.
- Subsequent work, including Kaminetsky et al. on subcutaneous autoinjector delivery, showed steady-state concentrations reached on a comparable timeline.
- Because fat releases more slowly, subcutaneous administration produces a lower initial peak and a more sustained release — flatter pharmacokinetics across the interval.
For decades the answer was a long needle into the glute every two weeks, and most people assumed that was simply what testosterone therapy involved. It is not, and it has not been for some years. The shift to a short insulin-style needle into the fat layer changed the experience substantially — and, more usefully, changed the shape of the curve between doses.
How each route works
Intramuscular places the oil into muscle — most often the gluteal muscle, the vastus lateralis in the outer thigh, or the deltoid. Muscle is well vascularised, so the depot is drawn on relatively quickly.
Subcutaneous places it into the fat layer just under the skin, typically the abdomen or upper thigh. Fat has a sparser blood supply, so the same depot releases more slowly.
Both work for the same underlying reason. Testosterone esters — cypionate and enanthate — are dissolved in a carrier oil, and the oil forms a reservoir that releases hormone over days. The tissue holding that reservoir changes the release rate, not the mechanism.
Does subcutaneous actually deliver the same?
This was the reasonable objection when the practice started spreading, and it has been studied. Spratt et al. (J Clin Endocrinol Metab 2017) compared weekly subcutaneous and intramuscular administration and found subcutaneous produced serum testosterone comparable to intramuscular, with patients reporting a preference for it. Subsequent work, including Kaminetsky et al. on subcutaneous autoinjector delivery, showed steady-state concentrations reached on a comparable timeline.
So the short version: at the same dose, the route is not costing you serum testosterone. That is the finding that made the change possible.
The real advantage is the shape of the curve
What differs is not the average but the swing. Because fat releases more slowly, subcutaneous administration produces a lower initial peak and a more sustained release — flatter pharmacokinetics across the interval.
That matters because most of the unpleasant parts of injectable therapy are peak-driven rather than average-driven. A sharp early peak drives a corresponding rise in aromatisation to oestradiol, and the associated water retention, and the mood variability some people describe in the day or two after a shot. Flattening the peak tends to flatten those with it.
The same logic explains the move away from large fortnightly doses. A single large dose every two weeks produces a high peak and a long trough, and people frequently feel the difference between the two ends. Splitting the same weekly total into more frequent, smaller injections narrows that range considerably. This is why twice-weekly subcutaneous dosing has become a common pattern — though frequency, dose and ester are decisions for your prescriber, not defaults to adopt from an article.
Comfort, and why it decides adherence
| Factor | Subcutaneous | Intramuscular |
|---|---|---|
| Needle | 27-30 gauge, 1/2-5/8 inch | 22-25 gauge, 1-1.5 inch |
| Injection discomfort | Minimal | Moderate; post-injection soreness common |
| Self-administration | Straightforward | Manageable, awkward for glute |
| Bleeding or bruising | Uncommon | More common |
| Sites available | Abdomen, upper thigh | Glute, thigh, deltoid |
| Volume tolerated | Smaller (roughly up to 0.5 mL) | Larger volumes fine |
Comfort sounds like a soft consideration and is not. A therapy is only as good as the consistency with which it is taken, and a weekly event people quietly dread is one they eventually start postponing. A needle you barely feel, administered into your own abdomen in a few seconds, removes the main reason people drift off schedule.
What good technique looks like
Your prescriber or pharmacy should train you on this directly, and their instruction supersedes anything written here. In outline:
- Needle: a 27-29 gauge, 1/2-5/8 inch insulin-style syringe.
- Site: abdomen, an inch or two to the side of the navel, or the upper outer thigh.
- Pinch a fold of fatty tissue between thumb and finger.
- Insert at 45° or 90° depending on how much subcutaneous tissue you have. See the body fat calculator if you are unsure where you sit.
- Inject slowly — 30 to 60 seconds for the volume. Rushing is the most common cause of a sore site.
- Light pressure after withdrawal; no vigorous rubbing.
- Rotate sites every time. Repeatedly using one spot is what produces the firm lumps some long-term users develop.
Warming the vial in your hands for a minute makes the oil less viscous and the injection noticeably easier. Contact your prescriber about persistent redness, swelling, warmth or a lump that does not settle within a few days.
When intramuscular is still the right call
Subcutaneous being the usual default does not make intramuscular obsolete. It remains the better option when:
- The volume is larger than the subcutaneous space comfortably takes.
- Body fat is very low, leaving little subcutaneous tissue to inject into.
- Skin reactions or persistent site irritation develop subcutaneously.
- A specific preparation is formulated for intramuscular use.
- The prescriber has a clinical reason particular to that patient.
The clinical pearl: The route matters less than the interval. Moving from one large injection every two weeks to smaller, more frequent doses is the single change that flattens the peak-to-trough swing most — and subcutaneous administration is what makes frequent dosing comfortable enough to sustain.
Bottom line
Subcutaneous injection delivers serum testosterone comparable to intramuscular at the same dose, with a lower peak and a flatter curve between doses, a much smaller needle, and easier self-administration. That combination is why it has become the usual modern default. Intramuscular remains appropriate for larger volumes, very low body fat, site reactions and specific clinical situations. Whichever route applies to you, the dose, the ester, the interval and the technique are set by your prescribing physician — and the interval is usually the variable with the biggest effect on how the week actually feels.
Educational content, not medical advice, and not instructions to self-administer any medication. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary. Route, dose, frequency and injection technique are determined and taught by your prescribing physician after individual evaluation.
